
|Articles|December 3, 2007
FDA approves Alcon steroid
The FDA has approved Triesence, Alcon's preservative-free synthetic coricosteroid for visualization during vitrectomy.
Advertisement
The FDA has approved Triesence, Alcon's preservative-free synthetic coricosteroid for visualization during vitrectomy.
Triesence injectable suspension, the active ingredient of which is triamcinolone acetonide, is indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids, in addition to being used for visualization during vitrectomy.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
IGS 2026: Navigating MIGS and other modern glaucoma procedures
2
IGS 2026: The expanding role of artificial intelligence in ophthalmology
3
IGS 2026: Current clinical perspectives on optic disc drusen
4
IGS 2026: Considering OCT in neuro-ophthalmology and neurological diseases
5





























